Ryvu Therapeutics Valuation

Is RVU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RVU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RVU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RVU's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RVU?

Key metric: As RVU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RVU. This is calculated by dividing RVU's market cap by their current revenue.
What is RVU's PS Ratio?
PS Ratio	11.2x
Sales	zł91.18m
Market Cap	zł1.02b

RVU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.4x
Enterprise Value/EBITDA	-9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RVU's PS Ratio compare to its peers?

The above table shows the PS ratio for RVU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.8x
SLV Selvita	2.9x	16.3%	zł982.0m
CLN Celon Pharma	5.1x	3.2%	zł1.4b
MDB Medicofarma Biotech	26.1x	n/a	zł27.9m
SVE Synthaverse	4.9x	n/a	zł306.4m
RVU Ryvu Therapeutics	11.2x	14.9%	zł1.0b

Price-To-Sales vs Peers: RVU is expensive based on its Price-To-Sales Ratio (11.2x) compared to the peer average (9.8x).

Price to Sales Ratio vs Industry

How does RVU's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: RVU is expensive based on its Price-To-Sales Ratio (11.2x) compared to the European Life Sciences industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is RVU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RVU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	11.2x
Fair PS Ratio	7.7x

Price-To-Sales vs Fair Ratio: RVU is expensive based on its Price-To-Sales Ratio (11.2x) compared to the estimated Fair Price-To-Sales Ratio (7.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RVU forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	zł44.25	zł80.90 +82.8%	20.4%	zł108.10	zł67.00	n/a	4
Nov ’25	zł44.80	zł78.70 +75.7%	16.4%	zł99.30	zł67.00	n/a	4
Oct ’25	zł52.40	zł78.70 +50.2%	16.4%	zł99.30	zł67.00	n/a	4
Sep ’25	zł53.70	zł77.95 +45.2%	17.5%	zł99.30	zł64.00	n/a	4
Aug ’25	zł53.60	zł77.95 +45.4%	17.5%	zł99.30	zł64.00	n/a	4
Jul ’25	zł49.00	zł77.95 +59.1%	17.5%	zł99.30	zł64.00	n/a	4
Jun ’25	zł54.00	zł70.83 +31.2%	9.5%	zł80.00	zł64.00	n/a	3
May ’25	zł49.50	zł73.13 +47.7%	9.7%	zł80.00	zł64.00	n/a	4
Apr ’25	zł55.20	zł71.88 +30.2%	8.5%	zł80.00	zł64.00	n/a	4
Mar ’25	zł59.00	zł73.13 +23.9%	9.7%	zł80.00	zł64.00	n/a	4
Feb ’25	zł56.00	zł71.43 +27.5%	12.1%	zł80.00	zł61.70	n/a	4
Jan ’25	zł57.50	zł71.43 +24.2%	12.1%	zł80.00	zł61.70	n/a	4
Dec ’24	zł59.70	zł71.43 +19.6%	12.1%	zł80.00	zł61.70	n/a	4
Nov ’24	zł60.50	zł70.43 +16.4%	10.5%	zł80.00	zł61.70	zł44.80	4
Oct ’24	zł65.20	zł72.57 +11.3%	11.1%	zł81.00	zł61.70	zł52.40	3
Sep ’24	zł60.90	zł72.57 +19.2%	11.1%	zł81.00	zł61.70	zł53.70	3
Aug ’24	zł58.30	zł72.57 +24.5%	11.1%	zł81.00	zł61.70	zł53.60	3
Jul ’24	zł60.40	zł72.23 +19.6%	10.7%	zł80.00	zł61.70	zł49.00	3
Jun ’24	zł56.00	zł72.23 +29.0%	10.7%	zł80.00	zł61.70	zł54.00	3
May ’24	zł56.00	zł72.23 +29.0%	10.7%	zł80.00	zł61.70	zł49.50	3
Apr ’24	zł59.20	zł72.23 +22.0%	10.7%	zł80.00	zł61.70	zł55.20	3
Mar ’24	zł63.70	zł62.90 -1.3%	21.5%	zł80.00	zł47.00	zł59.00	3
Feb ’24	zł53.40	zł55.70 +4.3%	15.6%	zł64.40	zł47.00	zł56.00	2
Jan ’24	zł49.25	zł55.70 +13.1%	15.6%	zł64.40	zł47.00	zł57.50	2
Dec ’23	zł55.90	zł55.70 -0.4%	15.6%	zł64.40	zł47.00	zł59.70	2
Nov ’23	zł41.00	zł55.70 +35.9%	15.6%	zł64.40	zł47.00	zł60.50	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.